Tim Knotnerus is CEO of AgomAb Therapeutics, a privately held Belgian based biotech company developing hepatocyte growth factor (HGF) mimetic antibodies. While the company’s antibodies maintain the full therapeutic potential of HGF, they display the excellent drug-like properties of antibodies, holding the promise for regeneration of tissues in a variety of clinical indications. In March 2019, the team closed a $23 million series A financing round from a syndicate of venture capital and strategic investors to fund the non-clinical development of the lead compound. Prior to AgomAb, Tim was VP Corporate Development at AM-Pharma where he and the team conducted a phase IIb trial in patients with sepsis-associated acute kidney injury, signed a $600M option-to-acquisition deal with Pfizer and raised a $133M private financing round. Prior to that, Tim was a senior associate at Aescap Venture, a venture capital fund investing in European medical companies, where he was instrumental in the financing and support of various portfolio companies. Tim holds an executive MBA from IMD (Switzerland), where he was named Valedictorian, and gained a Science and Innovation Masters and a Drug Innovation Masters, both with honors from Utrecht University (NL).